

# **Zydus Wellness Limited**

October 29, 2020

#### Rating

Instruments	Amount (Rs. crore)	Rating <sup>1</sup>	Rating Action
Non-Convertible Debentures Issue	-	•	Withdrawn

Details of Instruments in Annexure-1

# Detailed Rationale, Key Rating Drivers and Detailed Description of The Key Rating Drivers

CARE has withdrawn the outstanding ratings of 'CARE AA+; Stable' (Double A Plus; Outlook: Stable) assigned to the Non-Convertible Debentures (NCDs) of Zydus Wellness Limited (ZWL) with immediate effect. The above action has been taken at the request of ZWL and 'No Dues Certificate' received from the debenture trustee/debenture holder for the NCDs rated by CARE as these have been repurchased from the open market by ZWL and extinguished in full; consequently, there is no amount outstanding against these NCDs.

Analytical approach: Not Applicable

#### Applicable Criteria

Policy on Withdrawal of ratings

### **About the Company**

ZWL is engaged in the manufacturing, branding and distribution of health food and personal care products. Earlier ZWL operated as a consumer product division of Cadila Healthcare Limited (CHL). During June 2006, CHL acquired majority equity stake in an already listed entity Carnation Nutra Analogue Foods Limited (Carnation). After acquisition of Carnation, CHL's consumer product division was de-merged from CHL and hived off to Carnation. Carnation was renamed as Zydus Wellness Limited in 2009. Originally, ZWL used to sell its products under three brands i.e. "Sugar-Free" (Sugar substitute), "Everyuth" (Skin Care) and "Nutralite" (Table spread) which are well-established brands in their respective categories.

In January 2019, CHL through its subsidiary ZWL, acquired Heinz India Private Limited (HIPL) (wholly owned subsidiary of Heinz Italia SPA) for a consideration of around Rs.4,600 crore. The deal included acquisition of business of HIPL's four brands Complan, Glucon-D, Nycil and Sampriti Ghee, its two manufacturing units in Aligarh (Uttar Pradesh) and Sitarganj (Uttarakhand) and all operational assets and liabilities along-with associated distribution network. The acquisition was funded through NCDs of Rs.1,500 crore raised by ZWL and rest through a mix of equity infusion (including from CHL and Zydus Family Trust) and internal accruals.

During October 2020, ZWL repurchased all the NCDs issued by it (and rated by CARE) from the open market and cancelled the same leading to extinguishment of the entire NCDs; consequently, there is no amount outstanding against the rated NCD. This repurchase was financed partly through infusion of equity by promoters (Zydus Family Trust - preferential allotment of Rs.350 crore) and institutional investors (QIP placement of Rs.650 crore; mainly domestic MFs), and partly through surplus liquidity available at its parent level i.e. CHL's level. CHL through its subsidiary has extended unsecured loans to 7WI

100110 10 1111				
Priof Einancials (Ps. crore)	FY18 (A)	FY19 (A)	FY20 (A)	
Brief Financials (Rs. crore)		Consolidated		
Total operating income	536	863	1,772	
PBILDT	145	195	327	
PAT	137	171	142	
Overall gearing (times)*	0.04	0.46	0.43	
PBILDT Interest coverage (times)	85.21	6.47	2.33	

A – Audited \*Considering acquired goodwill of Rs.3,797 crore as fixed assets and part of its net worth.

As per its published results on the stock exchange, on a consolidated basis, ZWL reported a PAT of Rs.89 crore on a total operating income (TOI) of Rs.537 crore during Q1FY21 as against a PAT of Rs.80 crore on a TOI of Rs.623 crore during Q1FY20.

Status of non-cooperation with previous CRA: Not Applicable

Any other information: Not Applicable

Rating History for last three years: Please refer Annexure-2

Complexity level of instrument rated for the company: Please refer Annexure-3

 $^1$ Complete definition of the ratings assigned are available at  $\underline{www.careratings.com}$  and other CARE publications



# Annexure-1: Details of Instruments/Facilities

Name of the Instrument	Date of Issuance	ISIN No.	Coupon Rate	Maturity Date	Size of the Issue (Rs. crore)	Rating assigned along with Rating Outlook
Non-Convertible Debentures		INE768C07017		-	-	
Non-Convertible Debentures	January 16, 2019	INE768C07025	-	-	-	Withdrawn
Non-Convertible Debentures		INE768C07033		-	-	

# Annexure-2: Rating History of last three years

			Current Ratings		Rating history			
Sr. No.	Instrument/Bank	Туре	Amount Outstanding (Rs. crore)	Rating	Date(s) & Rating(s) assigned in 2019-2020	Date(s) & Rating(s) assigned in 2018-2019	Date(s) & Rating(s) assigned in 2017-2018	Date(s) & Rating(s) assigned in 2016-2017
					2019-2020	2010-2019	2017-2016	2010-2017
	Debentures-Non				1)CARE AA+;	1)CARE AA+;		
1.	Convertible Debentures	LT	-	Withdrawn	Stable	Stable	-	-
	Convertible Debelltures				(02-Jan-20)	(31-Dec-18)		

# Annexure 3: Complexity level of various instruments rated for this company

Sr. No.	Name of the Instrument	Complexity Level
1.	Non-Convertible Debentures	Complex

## **Annexure 4: List of entities Consolidated in ZWL**

Sr. No.	Name of the entity	% Shareholding by ZWL as on March 31, 2020	Nature of relationship
1	Liva Nutritions Limited	100.00%	Subsidiary
2	Liva Investments Limited	100.00%	Subsidiary
3	Zydus Wellness Products Limited	98.63%	Subsidiary
4	Zydus Wellness International DMCC	100.00%	Subsidiary

**Note on complexity levels of the rated instrument:** CARE has classified instruments rated by it on the basis of complexity. This classification is available at www.careratings.com. Investors/market intermediaries/regulators or others are welcome to write to care@careratings.com for any clarifications.



## **Contact Us**

#### **Media Contact**

Mr. Mradul Mishra

Contact No.: +91-22-6837 4424

Email ID - mradul.mishra@careratings.com

# Analyst Contact - 1

Name: Krunal Modi Tel: 079 - 40265614 Mobile # 8511190084

Email: krunal.modi@careratings.com

# Analyst Contact - 2

Name: Ranjan Sharma Tel: 079 - 40265617 Mobile # 9824021823

Email: ranjan.sharma@careratings.com

### **Business Development Contact**

Mr. Deepak Prajapati

Contact No.: +91-79-4026 5656

Email ID - deepak.prajapati@careratings.com

### **About CARE Ratings:**

CARE Ratings commenced operations in April 1993 and over two decades, it has established itself as one of the leading credit rating agencies in India. CARE is registered with the Securities and Exchange Board of India (SEBI) and also recognized as an External Credit Assessment Institution (ECAI) by the Reserve Bank of India (RBI). CARE Ratings is proud of its rightful place in the Indian capital market built around investor confidence. CARE Ratings provides the entire spectrum of credit rating that helps the corporates to raise capital for their various requirements and assists the investors to form an informed investment decision based on the credit risk and their own risk-return expectations. Our rating and grading service offerings leverage our domain and analytical expertise backed by the methodologies congruent with the international best practices.

### **Disclaimer**

CARE's ratings are opinions on the likelihood of timely payment of the obligations under the rated instrument and are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. CARE's ratings do not convey suitability or price for the investor. CARE's ratings do not constitute an audit on the rated entity. CARE has based its ratings/outlooks on information obtained from sources believed by it to be accurate and reliable. CARE does not, however, guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by CARE have paid a credit rating fee, based on the amount and type of bank facilities/instruments. CARE or its subsidiaries/associates may also have other commercial transactions with the entity. In case of partnership/proprietary concerns, the rating /outlook assigned by CARE is, inter-alia, based on the capital deployed by the partners/proprietor and the financial strength of the firm at present. The rating/outlook may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor in addition to the financial performance and other relevant factors. CARE is not responsible for any errors and states that it has no financial liability whatsoever to the users of CARE's rating.

Our ratings do not factor in any rating related trigger clauses as per the terms of the facility/instrument, which may involve acceleration of payments in case of rating downgrades. However, if any such clauses are introduced and if triggered, the ratings may see volatility and sharp downgrades.